Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

BMY Bristol-Myers Squibb

Watchlist
71.690
-0.020-0.03%
Trading Session 09/30 11:14 ET
Giving away premium quotes worth 5000 HKD/year to unlock more data
Get NOW
High
72.110
Open
71.780
Turnover
137.91M
Low
71.020
Pre Close
71.710
Volume
1.93M
Market Cap
153.08B
P/E(TTM)
23.82
52wk High
80.034
Shares
2.14B
P/E(Static)
22.98
52wk Low
52.009
Float Cap
151.79B
Bid/Ask %
-60.00%
Historical High
80.034
Shs Float
2.12B
Volume Ratio
0.69
Historical Low
9.089
Dividend TTM
2.11
Div Yield TTM
2.01
P/B
4.70
Dividend LFY
2.94%
Div Yield LFY
2.80%
Turnover Ratio
0.09%
Amplitude
1.52%
Avg Price
71.489
Lot Size
1
Float Cap
151.79B
Bid/Ask %
-60.00%
Historical High
80.034
Shs Float
2.12B
Volume Ratio
0.69
Historical Low
9.089
Dividend TTM
2.11
P/B
4.70
Dividend LFY
2.94%
Turnover Ratio
0.09%
Amplitude
1.52%
Avg Price
71.489
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company’s products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
CEO: Caforio M.D., Giovanni
Market: NYSE
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist
Back to the Top